SCHEMBL4042914

SCHEMBL4042914

NC(=O)c1c(F)ccc(Cl)c1Cl

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PBRM1 Q86U86 1/20 0.40
CASP1 P29466 1/20 0.37
KMT2A Q03164 2/20 0.37
ATM Q13315 1/20 0.37
SLC2A1 P11166 1/20 0.37
CES2 O00748 1/20 0.37
CES1 P23141 1/20 0.37
IDO1 P14902 1/20 0.37
GAA P10253 4/20 0.36
CDC7 O00311 2/20 0.36
PLK4 O00444 2/20 0.36
DYRK3 O43781 2/20 0.36
ROCK2 O75116 2/20 0.36
PRKD3 O94806 2/20 0.36
MAP4K4 O95819 2/20 0.36
INSR P06213 2/20 0.36
CDK1 P06493 2/20 0.36
PIM1 P11309 2/20 0.36
FGFR1 P11362 2/20 0.36
PRKACA P17612 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5800279 0.87 CES2 (0.39) PBRM1CASP1CES2CES1IDO1
SCHEMBL6818860 0.85 PBRM1 (0.41) PBRM1CASP1KMT2AATMSLC2A1
SCHEMBL8676513 0.83 PBRM1 (0.43) PBRM1CASP1KMT2AATMSLC2A1
SCHEMBL201397 0.82 HSD17B1 (0.41) PBRM1CES2CES1PARP1
SCHEMBL27630874 0.81 ALDH1A1 (0.46) KMT2ASLC2A1CES2CES1GAA
SCHEMBL7820374 0.81 DPP4 (0.48) CASP1SLC2A1CES2CES1GAA
SCHEMBL4026715 0.80 POLB (0.42) PBRM1CASP1CES2CES1GAA
Hydrochloric Acid SCHEMBL8380885 0.80 PBRM1 (0.41) PBRM1CASP1KMT2AATMSLC2A1
SCHEMBL14661433 0.80 DGAT1 (0.39) PBRM1CASP1CES2CES1IDO1
SCHEMBL3101770 0.79 NOTUM (0.37) KMT2ASLC2A1CES2CES1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1846410-B1 DIHYDROQUINAZOLINONES AS 5HT MODULATORS BRISTOL MYERS SQUIBB CO (US) 2009-01-21 EP disclosed
EP-1846410-A2 DIHYDROQUINAZOLINONES AS 5HT MODULATORS Bristol-Myers Squibb Company (US) 2007-10-24 EP disclosed
US-7238702-B2 Dihydroquinazolinones as 5HT modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2007-07-03 US disclosed
WO-2006086464-A2 DIHYDROQUINAZOLINONES AS 5HT MODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2006-08-17 WO disclosed
US-20060178386-A1 Dihydroquinazolinones as 5HT modulators BRISTOL-MYERS SQUIBB COMPANY 2006-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060178386-A1 Dihydroquinazolinones as 5HT modulators HTR3B, HTR2C, HTR2B PBRM1 2795/4885CASP1 3669/4885KMT2A 2819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.